Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma
Authors:
- Tim EisenTETim Eisen
- José ThomasJTJosé Thomas
- Wilson H. MillerWMWilson H. Miller
- Martin GoreMGMartin Gore
- Pascal WolterPWPascal Wolter
- Petr KavanPKPetr Kavan
- José A. López MartínJMJosé A. López Martín
- Pilar LardelliPLPilar Lardelli
- 1 June 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 19 (3) , 185-192
Abstract
The objective of this study was to evaluate the antitumor activity and safety profile of 5 mg/m2 plitidepsin administered as a 3-h continuous intravenous infusion every 2 weeks to patients with advanced malignant melanoma who relapsed or progressed after one line of systemic therapy. Objective response rate (primary efficacy endpoint) was evaluated according to Response Evaluation Criteria In Solid Tumors and toxicity was assessed using National Cancer Institute -Common Toxicity Criteria Version 2.0. Of 39 enrolled patients (median age: 53 years), 37 patients were treated who received a total of 167 treatment cycles (median: 3 cycles per patient; range: 1–32). All patients had received prior systemic therapy with a median of one line per patient (range: 1–6 lines). Of the 35 evaluable patients, two dacarbazine-resistant patients (5.7%) with metastatic cutaneous melanoma achieved partial responses. Five other patients (14.3%) reported stable disease (median stable disease duration: 3.5 months; range: 2.2–15.8 months). Therefore, the rate of tumor growth control was 20.0%. With a median follow-up of 11.0 months, the median progression-free survival was 1.3 months and the median overall survival was 3.5 months. Six patients (16.2%) had the following treatment-related grade 3/4 adverse events: myalgia (n = 3), injection-site reaction (n = 2), hypersensitivity, hypotension, and fatigue (n = 1 each). One patient was withdrawn from the trial because of grade 4 hypersensitivity reaction and hypotension. No severe neutropenia was reported. Plitidepsin showed a minor degree of antitumor activity in patients with refractory advanced malignant melanoma. Further evaluation of plitidepsin in combination schedules may be warranted.Keywords
This publication has 24 references indexed in Scilit:
- Immunotherapy of melanoma: a critical review of current concepts and future strategiesExpert Opinion on Biological Therapy, 2007
- Aplidin® induces JNK-dependent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation, and MKP-1 phosphatase downregulationCell Death & Differentiation, 2006
- VEGF inhibition and cytotoxic effect of aplidin in leukemia cell lines and cells from acute myeloid leukemiaAnnals of Oncology, 2005
- JNK activation is critical for Aplidin™-induced apoptosisOncogene, 2004
- In vitro cytotoxicity of aplidin and crossresistance with other cytotoxic drugs in childhood leukemic and normal bone marrow and blood samples: a rational basis for clinical developmentLeukemia, 2003
- Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4Leukemia, 2003
- AplidinTM Induces Apoptosis in Human Cancer Cells via Glutathione Depletion and Sustained Activation of the Epidermal Growth Factor Receptor, Src, JNK, and p38 MAPKJournal of Biological Chemistry, 2003
- Aplidin™ induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C δOncogene, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989